S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Stock market today: Asian shares mixed, with most regional markets closed after Wall St ticks higher
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
Low Beta Stocks To Offset A Possible Hard Landing
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Stock market today: Asian shares mixed, with most regional markets closed after Wall St ticks higher
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
Low Beta Stocks To Offset A Possible Hard Landing
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Stock market today: Asian shares mixed, with most regional markets closed after Wall St ticks higher
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
Low Beta Stocks To Offset A Possible Hard Landing
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Stock market today: Asian shares mixed, with most regional markets closed after Wall St ticks higher
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
Low Beta Stocks To Offset A Possible Hard Landing
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
NASDAQ:CERE

Cerevel Therapeutics (CERE) Stock Forecast, Price & News

$22.17
+1.12 (+5.32%)
(As of 09/28/2023 ET)
Compare
Today's Range
$21.51
$22.24
50-Day Range
$20.26
$30.73
52-Week Range
$19.85
$35.98
Volume
745,728 shs
Average Volume
618,449 shs
Market Capitalization
$3.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.90

Cerevel Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
52.9% Upside
$33.90 Price Target
Short Interest
Bearish
8.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.08mentions of Cerevel Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Decreasing
From ($2.59) to ($2.70) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

606th out of 969 stocks

Pharmaceutical Preparations Industry

289th out of 455 stocks


CERE stock logo

About Cerevel Therapeutics (NASDAQ:CERE) Stock

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CERE Price History

CERE Stock News Headlines

Ceres Power: Business Model Concerns Persist
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
Cerevel Therapeutics (NASDAQ:CERE) Stock Price Down 3.2%
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
Cerevel Therapeutics falls on delayed data readouts
See More Headlines
Receive CERE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CERE Company Calendar

Last Earnings
8/02/2023
Today
9/28/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Coal & Consumable Fuels
Sector
Medical
Current Symbol
NASDAQ:CERE
CUSIP
15677310
Fax
N/A
Employees
322
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.90
High Stock Price Forecast
$46.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+53.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

Net Income
$-351,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.33 per share

Miscellaneous

Free Float
149,456,000
Market Cap
$3.49 billion
Optionable
Not Optionable
Beta
1.42
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. N. Anthony Coles Jr. (Age 63)
    M.P.H., Exec. Chairman
    Comp: $1.14M
  • Mr. Mark Bodenrader (Age 50)
    VP of Fin. & Chief Accounting Officer
    Comp: $496.17k
  • Dr. John J. Renger Ph.D. (Age 54)
    Chief Scientific Officer
    Comp: $779.75k
  • Dr. Ramiro Sanchez M.D. (Age 62)
    Chief Medical Officer
    Comp: $805.13k
  • Mr. Ronald C. Renaud Jr. (Age 54)
    M.B.A., MBA, Pres, CEO & Director
  • Dr. Susan Altschuller M.B.A. (Age 41)
    Ph.D., Chief Financial Officer
  • Mr. Matthew Calistri
    VP of Investor Relations
  • Mr. Scott M. Akamine J.D. (Age 38)
    Chief Legal Officer & Corp. Sec.
  • Mr. Kenneth A. DiPietro (Age 64)
    Chief HR Officer
  • Ms. Kathleen Tregoning M.A. (Age 52)
    Chief Corp. Affairs Officer













CERE Stock - Frequently Asked Questions

Should I buy or sell Cerevel Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CERE shares.
View CERE analyst ratings
or view top-rated stocks.

What is Cerevel Therapeutics' stock price forecast for 2023?

11 brokers have issued 12 month price targets for Cerevel Therapeutics' stock. Their CERE share price forecasts range from $22.00 to $46.00. On average, they predict the company's stock price to reach $33.90 in the next year. This suggests a possible upside of 52.9% from the stock's current price.
View analysts price targets for CERE
or view top-rated stocks among Wall Street analysts.

How have CERE shares performed in 2023?

Cerevel Therapeutics' stock was trading at $31.54 on January 1st, 2023. Since then, CERE stock has decreased by 29.7% and is now trading at $22.17.
View the best growth stocks for 2023 here
.

Are investors shorting Cerevel Therapeutics?

Cerevel Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 6,020,000 shares, an increase of 10.7% from the August 31st total of 5,440,000 shares. Based on an average daily trading volume, of 659,700 shares, the short-interest ratio is currently 9.1 days. Currently, 8.8% of the shares of the stock are sold short.
View Cerevel Therapeutics' Short Interest
.

When is Cerevel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CERE earnings forecast
.

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) posted its earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.02. During the same period in the prior year, the business posted ($0.61) EPS.

What ETFs hold Cerevel Therapeutics' stock?
What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).

What is Cerevel Therapeutics' stock symbol?

Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE."

Who are Cerevel Therapeutics' major shareholders?

Cerevel Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (6.41%), BlackRock Inc. (3.08%), State Street Corp (1.76%), Artal Group S.A. (1.04%), Geode Capital Management LLC (0.86%) and Polar Capital Holdings Plc (0.58%). Insiders that own company stock include Abraham Ceesay, Deval L Patrick, Gabrielle Sulzberger, John Renger, Marijn E Dekkers, Mark Bodenrader, N Anthony Coles, Paul D Burgess, Perceptive Advisors Llc and Ronald C Renaud Jr.
View institutional ownership trends
.

How do I buy shares of Cerevel Therapeutics?

Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerevel Therapeutics' stock price today?

One share of CERE stock can currently be purchased for approximately $22.17.

How much money does Cerevel Therapeutics make?

Cerevel Therapeutics (NASDAQ:CERE) has a market capitalization of $3.49 billion. The biotechnology company earns $-351,510,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Cerevel Therapeutics have?

The company employs 322 workers across the globe.

How can I contact Cerevel Therapeutics?

Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The official website for the company is ceres.net. The biotechnology company can be reached via phone at 844-304-2048 or via email at ir@cerevel.com.

This page (NASDAQ:CERE) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -